NUVB vs AQST โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AQST Captures Institutional Edge (2โ1 Pillars ยท 3โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aquestive Therapeutics, Inc. Common Stock (AQST) driven by superior Momentum & Technical, Options & Structure while NUVB counters with relative strength in Growth & Margin. Fundamentally, NUVB trades at N/M Forward P/E with -61.2% operating margin (+242.6% YoY revenue) versus AQST at N/M Forward P/E and -114.1% operating margin (-41.0% YoY). In options structure, NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro) against AQST sits in BREAKDOWN (64th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NUVB Revenue | AQST Revenue | NUVB Op. Margin | AQST Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $70M | N/A | -72.6% | AQST |
| FY2019 | N/A | $50M | N/A | -100.1% | AQST |
| FY2020 | N/A | $50M | N/A | -93.6% | AQST |
| FY2021 | N/A | $50M | N/A | -68.2% | AQST |
| FY2022 | N/A | $50M | N/A | -88.2% | AQST |
| FY2023 | N/A | $50M | N/A | -29.9% | AQST |
| FY2024 | $10M | $60M | -7527.3% | -53.5% | AQST |
| FY2025 | $60M | $40M | -338.7% | -159.5% | AQST |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NUVB | AQST | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.3B | $465.7M | Larger Scale | NUVB |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +242.6% | -41.0% | Higher Growth | NUVB |
| Operating Margin (TTM) Profitability | -61.2% | -114.1% | Higher Margin | NUVB |
| Net Profit Margin Profitability | -67.4% | -162.3% | Higher Margin | NUVB |
| Return on Equity (ROE) Capital Efficiency | -49.1% | 0.0% | Higher ROE | AQST |
| 52-Week Range Position Momentum | 2% ($4โ$10) | 14% ($3โ$7) | Stronger Trend | AQST |
| Beta / 30D Volatility Risk Regime | 1.52ฮฒ ยท 55% Vol | 0.89ฮฒ ยท 56% Vol | Lower Realized Risk | NUVB |
| Unified Institutional Score Composite Signal | 61.0 / 100 (BUY) | 62.9 / 100 (BUY) | Higher Composite | AQST |